Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
Zevra Therapeutics (ZVRA) reported a Q3 loss of $0.69 per share, missing the Zacks Consensus Estimate of a $0.44 loss. This is a larger loss compared to $0.40 per share a year ago.
November 13, 2024 | 12:15 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Zevra Therapeutics reported a larger-than-expected Q3 loss of $0.69 per share, missing the consensus estimate and showing a decline from the previous year's loss.
The reported loss of $0.69 per share is significantly worse than the expected loss of $0.44, indicating financial underperformance. This is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100